“Low-dose estrogen may help if breast cancer recurs - Tehran Times” plus 4 more

---

• Low-dose estrogen may help if breast cancer recurs - Tehran Times
• Study: Lung cancer pill works for some - Chippewa Herald
• The Lance Armstrong Foundation Premieres the LIVESTRONG - Market Wire
• Cindy's Avon in Fontana will hold fundraiser to benefit breast cancer ... - Fontana Herald News
• Power3 Medical Products, Inc. Files for 3 Patents On Blood Test for ... - MSN Money

Low-dose estrogen may help if breast cancer recurs - Tehran Times Posted: 20 Aug 2009 08:29 AM PDT WASHINGTON (Reuters) –- A very low dose of estrogen might help women whose breast cancer has come back after treatment, researchers reported on Tuesday. Even though most treatments are aimed at stopping estrogen from fueling tumors, the researchers said after years of this therapy the body may need some of the hormone to fight them off. Their findings, published in the Journal of the American Medical Association, suggest a cheap way to help some patients with advanced breast cancer. Dr. Matthew Ellis of Washington University School of Medicine in St. Louis and colleagues studied 66 women with advanced breast cancer who had been treated with newer drugs called aromatase inhibitors. They include Pfizer's Aromasin, Novartis's Femara, and AstraZeneca Plc's Arimidex. "The women in the study had all experienced a relapse while on estrogen-lowering drugs, and their disease was progressing," Ellis said in a statement. "So they were faced with undergoing chemotherapy. We found that estrogen treatment stopped disease progression in many patients and was much better tolerated than chemotherapy would have been." They gave the women a form of estrogen called estradiol, in both high and very low doses. Both doses helped 30 percent of the women, Ellis and colleagues found. "We demonstrated clearly that the low dose was better tolerated than the high dose and was just as effective for controlling metastatic disease," Ellis said. The treatment was not always permanent. In 30 percent of the women helped by the estrogen, the tumors started growing again. But going back on the aromatase inhibitors -- a daily pill that is far less toxic than chemotherapy -- helped a third of these women. More than 400,000 women die from breast cancer globally every year. About 75 percent of breast cancers are estrogen-receptor-positive, meaning they are fed by estrogen, and treatment with drugs such as tamoxifen and the aromatase inhibitors cuts off this supply of hormones. This posting includes an audio/video/photo media file: Download Now

Study: Lung cancer pill works for some - Chippewa Herald Posted: 20 Aug 2009 12:04 PM PDT The research released Wednesday is the first to show Iressa can be more effective than chemotherapy as a first-line treatment, and some experts are hopeful it will prompt the Food and Drug Administration to allow wide use of the drug, made by AstraZeneca PLC. Others are doubtful. Though the study shows an effect on cancer growth over one year, the drug's impact on long-term survival is still in question. Also, the study was done in Asia, and the drug seems to work best with specific patients — Asians, women and nonsmokers who carry a specific gene mutation. "I'd venture to say that additional studies will be requested in the United States population," said Dr. Len Lichtenfeld, the American Cancer Society's deputy chief medical officer. AstraZeneca, which funded the study, is not planning a new push for expanded FDA approval of the drug, a company spokeswoman said. But the company is continuing to share data about the drug with federal health officials, she added. Iressa is a daily pill that more precisely targets cancer rather than healthy cells. It's an attractive alternative to standard chemotherapy, which involves trips to a hospital or clinic for infusions of poisonous chemicals that cause nausea and hair loss. In 2003, the FDA approved Iressa as a last-resort treatment for patients with the most common form of lung cancer, called non-small-cell lung cancer. The market was significant: Lung cancer kills more Americans than any other kind of tumor, and the Cancer Society estimates it will cause nearly 160,000 U.S. deaths this year. Non-small-cell lung cancer represents 85 percent of lung cancer cases. But in 2005, the FDA stopped allowing new patients to go on Iressa after early results from a federally sponsored study failed to show it improved lung cancer patients' survival rates. Another lung cancer pill, Roche Group's Tarceva, acts in a way similar to Iressa and remained on the market as a treatment for patients not helped by chemotherapy. There wasn't widespread outcry at the loss of Iressa because Tarceva remained available, said Dr. Edward Kim, a lung cancer specialist at the University of Texas M.D. Anderson Cancer Center. Interest in Iressa continued, though, as doctors have become increasingly interested in personalized approaches to cancer treatment. Studies have shown some drugs work better in certain breast and colon cancer patients than others, and earlier studies have found that Iressa dramatically shrunk tumors in patients who had lung cancers with a specific genetic mutation. That kind of case is seen in only a small fraction of U.S. lung cancer patients, but is much more common in Asia, scientists say. The latest study was led by Dr. Tony Mok of the Chinese University of Hong Kong, and involved about 1,200 patients throughout southeast Asia. The study group included the kind of people most likely to have the mutation, said Dr. Pasi Janne, a Dana-Farber Cancer Institute lung cancer specialist. The study measured cancer growth within a year after treatment, comparing patients who got Iressa to others who got chemotherapy. After one year, 25 percent on Iressa were alive without their cancer getting worse, as compared to 7 percent of those on chemo. Results were even better in those with the mutation. In those without the mutation, chemotherapy was more effective. The study was published online Wednesday by the New England Journal of Medicine. A second study released by the journal concluded that large-scale screening of lung cancer patients for the genetic mutation is feasible and can lead to wiser treatment. Mok and several of his fellow researchers received consulting and lecture fees from AstraZeneca, Roche and other drug companies. This posting includes an audio/video/photo media file: Download Now

The Lance Armstrong Foundation Premieres the LIVESTRONG - Market Wire Posted: 20 Aug 2009 10:31 AM PDT SOURCE: Lance Armstrong Foundation 500 Leaders From More Than 65 Countries to Convene in Fight Against Global Cancer Epidemic   http://www.livestrong.org   http://www.livestrongblog.org DUBLIN, IRELAND--(Marketwire - August 20, 2009) - Today, the Lance Armstrong Foundation (LAF) announced details of the LIVESTRONG Global Cancer Summit, an unparalleled three-day event -- August 24-26, 2009 -- that provides a unique platform for advocates to create a sustained movement that changes the course of cancer in history. More than 500 world leaders, representatives of corporations, non-governmental organizations and individual advocates will convene at the Royal Dublin Society in Dublin, Ireland to showcase the more than 300 commitments to cancer control made as part of the LIVESTRONG Global Cancer Campaign, an LAF initiative to urgently address the global cancer burden. The Summit will take place immediately following LAF Founder and Chairman, cancer survivor and champion cyclist Lance Armstrong's participation in the Tour of Ireland, Aug 21-23. "Cancer will be the leading cause of death next year unless we act on a global level," said Armstrong. "Our goal is to be the catalyst that brings everyone together to fight cancer -- from survivors, like me, to advocates from the farthest reaches of the globe, to world leaders and policymakers who must commit completely to the effort to avoid a public health catastrophe." Never before has a unified global movement against cancer been launched. Attendees will have the opportunity to connect with other advocates, network, gain media exposure and access tools and resources to help them mobilize in their own communities. The Summit marks an end as well as a new beginning. It serves as the culmination of seven months of awareness-raising by the Foundation during Armstrong's return season to professional cycling and launches a global grassroots movement to take action against cancer. "The Summit provides an invaluable opportunity to stand up for the 28 million cancer survivors worldwide and create a unified effort to control cancer through new commitments to action," said Doug Ulman, LAF President and CEO. "I am eager to join many of the world's public health leaders and advocates to set a path for reducing the burden of this disease that claims far too many lives." At the Summit, the first report detailing the global burden of cancer in economic terms will be unveiled. It is also the first report to quantify the global gap in cancer spending. The new report, "Breakaway: The global burden of cancer -- challenges and opportunities," was commissioned by LIVESTRONG and developed by the Economist Intelligence Unit with support from the American Cancer Society. Summit Schedule* -- Day One -- Addressing the Global Cancer Burden: By 2010, cancer is projected to be the leading cause of death worldwide. Yet, cancer is one of the most preventable and curable of the major life-threatening diseases facing the world today. The first day of the Summit will make the case for acting urgently to address the global cancer burden and introduce new commitments to cancer control by bringing together world leaders, corporations, non-governmental organizations and advocates in an unprecedented show of solidarity. Speakers include: -- Lance Armstrong, Chairman and Founder, LIVESTRONG -- Doug Ulman, President and Chief Executive Officer, LIVESTRONG -- Dr. Sanjay Gupta, Chief Medical Correspondent, CNN -- Dr. Werner Burkart, Deputy Director General, International Atomic Energy Agency -- Dr. John Seffrin, Chief Executive Officer, American Cancer Society -- Dr. Christopher P. Wild, Director, International Agency for Research on Cancer -- Lynn Faulds Wood, President, European Cancer Patient Coalition -- His Excellency Faisal A. Al-Fayez, Former Prime Minister, Jordan -- His Excellency Olusegun Obasanjo, Former President, Nigeria -- The Honorable Alojz Peterle, Member of European Parliament -- Prof. Judith Mackay, Senior Advisor, World Lung Foundation, and Senior Policy Advisor, World Health Organization -- Dr. Ala Alwan, Asst. Director-General, Noncommunicable Disease and Mental Health, World Health Organization -- His Excellency Dr. Abdullah Al-Rabeeah, Minister of Health, Saudi Arabia -- The Honorable Dr. José Ángel Córdova Villalobos, Secretary of Health, Mexico -- His Excellency Dr. Hatem El-Gabaly, Minister of Health, Egypt -- The Honorable Mary Harney TD, Minister of Health and Children, Ireland -- The Honorable Laurette Onkelinx, Minister of Social Affairs and Public Health, Belgium -- Dr. David Hill, President, International Union Against Cancer (UICC) -- Andy Miller, Executive Vice President - Mission, LIVESTRONG -- Prof. Jim Bishop AO, Chief Medical Officer, Australia -- Dr. Kisito Sheku Doah, Acting Chief Medical Office, Sierra Leone -- Prof. Alexander Eggermont, President, European CanCer Organisation -- Prof. Hamid Ghodse, Past President, International Narcotics Control Board -- Mark Parker, Chief Executive Officer, Nike -- Jonathan Thomas, President and Chief Executive Officer, American Century Companies, Inc. -- Caroline Roan, President, Pfizer Foundation -- Lorena Rojas, Mexican-Born Actress/Singer & Cancer Survivor -- Day Two -- Unity and Collaboration: Focus on the key role that unity and collaboration play in addressing the cancer burden. The day will explore how governments, corporations, non-governmental organizations and advocates can come together to address cancer. The Economist Intelligence Unit report, announced this day, will explore the global economic impact of cancer. Speakers include: -- Doug Ulman, President and Chief Executive Officer, LIVESTRONG -- Hana Ross, American Cancer Society -- Richard Stein, Economist Intelligence Unit -- Dr. John Seffrin, Chief Executive Officer, American Cancer Society -- Prof. Judith Mackay, Senior Advisor, World Lung Foundation, and Senior Policy Advisor, World Health Organization -- Dr. Montserrat Meiro-Lorenzo, Senior Public Health Specialist, Human Development Network, World Bank -- Prof. Tom Keane, National Cancer Control Programme of Ireland -- Harmala Gupta, CanSupport -- Samir Khleif, National Cancer Institute (NCI) -- Mohamed Shaalan, Breast Cancer Foundation of Egypt -- Dr. Paul Farmer, Co-Founder, Partners in Health -- Felicia Knaul, Chief Economist, Mexican Health Foundation -- Dr. Lawrence N. Shulman, Chief Medical Officer and Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute -- Dr. Luis Fernando de Barros Correia, Radio CBN -- Brother Charles Anthony, The Ormylia Foundation -- Pat Kelly, Campaign to Control Cancer -- Gabriel Madiye, The Shepherd's Hospice Sierra Leone -- Kim Thiboldeaux, The Wellness Community -- Dr. Tami Hultman, AllAfrica Global Media/allafrica.com -- Dr. Jean Anderson, Jhpiego -- Dr. Ian Garbett, University of Papua New Guinea -- Letha Sandison, Wrap Up Africa -- Prof. Michael Silbermann, Middle East Cancer Consortium -- Day Three -- Effective mobilization efforts will vary country by country and build upon each country's current approach. In some nations, mobilization must focus upon providing services for those touched by cancer. In other nations, leading the advocacy push that will result in important policy changes is central. There is no "one size fits all" solution. Speakers include: -- Lance Armstrong, Chairman and Founder, LIVESTRONG -- Doug Ulman, President and Chief Executive Officer, LIVESTRONG -- Greg Donaldson, American Cancer Society -- Dr. Xishan Hao, Chinese Anti-Cancer Association -- Rick Lyke, Pints for Prostates -- Dr. Alejandro Mohar, Instituto Nacional de Cancerologia -- Molebatsi Pooe-Shongwe, BreastSens -- Dr. M.R. Rajagopal, Trivandrum Institute of Palliative Care -- Thomas Crampton, Digital Media Specialist -- Jeremy Heimans, Purpose Campaigns -- Adam Garone, Movember Foundation -- Dr. Mateus Kambale Sahani, AGIR ENSEMBLE -- Maria Carla Sison, ICanServe Foundation -- The Honorable Mike Rann, Premier, South Australia For a detailed schedule of events and speakers at the LIVESTRONG Global Cancer Summit, submit a request to press@livestrong.org. The LIVESTRONG Global Cancer Summit is sponsored by an anonymous donor. It is also made possible with support from Ambassador Sponsors the American Cancer Society and Nike, Chairman's Sponsor EMD Serono and President's Sponsors HomeAway and Genentech. In September 2008, Armstrong announced the Foundation's commitment to making cancer a global priority at the Clinton Global Initiative Annual Meeting in New York. The LAF made this commitment after its worldwide research, conducted over 18 months, revealed widespread misconceptions, stigma and lack of awareness associated with cancer. In response, the LAF established the LIVESTRONG Global Cancer Campaign to urgently address the burden of cancer worldwide and support the 28 million people living with cancer around the globe. Cancer kills more people every year than AIDS, tuberculosis and malaria combined. It is estimated that cancer will be the leading cause of death worldwide by 2010. With such staggering statistics, the LAF recognized that a global challenge like cancer required a global movement. And so it began urging world leaders, leading cancer organizations and cancer survivors to join together by making commitments to take action in their communities to reduce the burden of cancer. In its inaugural year, the LIVESTRONG Global Cancer Campaign has broken new ground with successes to date in Australia, California, Mexico, Italy and throughout the Tour de France. For more information on the LIVESTRONG Global Cancer Campaign, please visit www.LIVESTRONGAction.org. About the Lance Armstrong Foundation: At the Lance Armstrong Foundation, we fight for the 28 million people around the world living with cancer today. There can be -- and should be -- life after cancer for more people. That's why we kick in at the moment of diagnosis, giving people the resources and support they need to fight cancer head-on. We find innovative ways to raise awareness, fund research and end the stigma about cancer that many survivors face. We connect people and communities to drive social change, and we call for state, national and world leaders to help fight this disease. Anyone anywhere can join our fight against cancer. Join us at www.LIVESTRONG.org. *Subject to change without notice. This posting includes an audio/video/photo media file: Download Now

Cindy's Avon in Fontana will hold fundraiser to benefit breast cancer ... - Fontana Herald News Posted: 20 Aug 2009 09:55 AM PDT Do not use usernames or passwords from your financial accounts! Note: Fields marked with an asterisk (*) are required! This posting includes an audio/video/photo media file: Download Now

Power3 Medical Products, Inc. Files for 3 Patents On Blood Test for ... - MSN Money Posted: 20 Aug 2009 08:29 AM PDT THE WOODLANDS, Texas, Aug. 20, 2009 (GLOBE NEWSWIRE) -- Power3 Medical Products, Inc. (OTCBB:PWRM), (www.power3medical.com), announced today that the company made significant advances in the technology for their BC-SeraPro serum protein based blood test for diagnosis of early stage breast cancer, as disclosed in recent filings of three pending US utility patent applications. "Roughly 200,000 women in the US and 1.2 million women worldwide are diagnosed with breast cancer each year. In the US, roughly 40,000 women die of the disease because the cancer is caught too late. In fact, nearly 1/2 of all cancers are missed as false negatives, and 75% of the biopsies of suspected breast cancer performed are false positive and therefore could have been avoided if there was a more accurate test that could be made readily available," said Ira L. Goldknopf, Ph.D., president and chief scientific officer of Power3. "We now have made strides towards this goal through refinements in our blood test for early stage detection of breast cancer." As disclosed in the patent applications, Power3 has identified a group of 22 blood serum proteins with abnormal concentrations in women with breast cancer. Using the company's BC-SeraPro platform, Power3 used these protein biomarkers to distinguish women with breast cancer from those with benign abnormal breast conditions and with normal breasts with sensitivities and specificities in the 80-90% range, in retrospective banked and prospective newly drawn samples from patients and controls. The biomarkers also distinguish between women with purely invasive primary breast cancer and women who also have ductal carcinoma in situ, which is often missed in mammograms. In addition, following the "Principals of Omic Medicine" that Dr. Goldknopf is promoting at international scientific meetings in the US and China, the company has disclosed methods for making biomarker specific antibodies for development of a user friendly commercial test for breast cancer. "We are enthusiastic about the increased value of BC-SeraPro with these 3 exemplary patent filings. Although we are striving to commercialize with our tests, we also recognize that this work has potential to alleviate much suffering," commented Ms. Helen R. Park, CEO of Power3. "Thus we will be publishing our results in the near term." About Power3 Medical Products, Inc.: Power3 Medical Products, Inc. (OTCBB:PWRM) (www.Power3Medical.com) is a leading Bio Medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3's patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. The Company continues to evolve and enhance its IP portfolio. Forward Looking Statement This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. CONTACT: Power3 Medical Products, Inc. Helen R. Park, M.S. 281-466-1600 Fax: 281-466-1481 hpark@power3medical.com 3400 Research Forest Drive Suite B2-3 Woodlands, TX 77381 GlobeNewswire, Inc.2009 Back to News Home MSN Money Search MSN Money Message Boards Site Status This posting includes an audio/video/photo media file: Download Now

You are subscribed to email updates from Add Images to any RSS Feed To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google Inc., 20 West Kinzie, Chicago IL USA 60610